These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 22468861

  • 1. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
    Balaji V, Balaji MS, Alexander C, Srinivasan A, Suganthi SR, Thiyagarajah A, Seshiah V.
    Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
    [Abstract] [Full Text] [Related]

  • 2. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 3. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF, Li H.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
    [Abstract] [Full Text] [Related]

  • 4. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
    Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S.
    Diabetes Res Clin Pract; 2012 Dec; 98(3):422-9. PubMed ID: 23068960
    [Abstract] [Full Text] [Related]

  • 5. Premixed insulin aspart 30 (Biasp 30) vs. premixed human insulin 30 (BHI 30) in gestational diabetes mellitus--a pilot study.
    Balaji V, Balaji MS, Alexander C, Ashalata S, Sheela Suganthi R, Suresh S, Seshiah V.
    J Assoc Physicians India; 2010 Feb; 58():99-101. PubMed ID: 20653150
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

  • 7. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
    Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A.
    BMC Endocr Disord; 2016 Jun 09; 16(1):35. PubMed ID: 27278922
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul 09; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 9. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
    Wolnik B, Hak L.
    Expert Opin Drug Saf; 2013 Mar 09; 12(2):137-44. PubMed ID: 23289795
    [Abstract] [Full Text] [Related]

  • 10. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr 09; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 11. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar 09; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 12. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep 09; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

  • 13. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E.
    Diabetes Metab; 2015 Jun 09; 41(3):223-30. PubMed ID: 25483023
    [Abstract] [Full Text] [Related]

  • 14. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar 09; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 15. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec 09; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 16. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul 09; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 17. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Jul 09; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr 09; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 19. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr 09; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 20. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug 09; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.